Skip to main content
Top
Published in: Journal of Gastroenterology 8/2017

01-08-2017 | Original Article—Liver, Pancreas, and Biliary Tract

Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients

Authors: Kensuke Kubota, Terumi Kamisawa, Kazuichi Okazaki, Shigeyuki Kawa, Kenji Hirano, Yoshiki Hirooka, Kazushige Uchida, Hideyuki Shiomi, Hirotaka Ohara, Kyoko Shimizu, Norikazu Arakura, Atsushi Kanno, Junichi Sakagami, Takao Itoi, Tetsuhide Ito, Toshiharu Ueki, Takayoshi Nishino, Kazuo Inui, Nobumasa Mizuno, Hitoshi Yoshida, Masanori Sugiyama, Eisuke Iwasaki, Atshishi Irisawa, Toru Shimosegawa, Yoshifumi Takeyama, Tsutomu Chiba

Published in: Journal of Gastroenterology | Issue 8/2017

Login to get access

Abstract

Background

The effect of maintenance steroid treatment (MST) in reducing the risk of relapse in patients with autoimmune pancreatitis (AIP) remains under debate. The aim of this study was to validate the effect of MST on AIP administered in accordance with the 2010 Japanese consensus guidelines.

Methods

The clinical data of patients with (n = 510) from 22 high-volume centers in Japan were studied. The primary endpoints were the relapse rates (RRs) in patients administered MST versus those not administered MST. The secondary endpoints were the optimal dose and duration of MST in terms of steroid toxicity and the predictors of relapse.

Results

The RRs were 10.0% within 1 year, 25.8% within 3 years and 35.1% within 5 years. The RR in the steroid therapy group reached a plateau at 42.7% at 7 years. In terms of the optimal dosage, the overall RR in the MST 5 mg/day group was 26.1%, which was significantly lower than that in the group which had discontinued steroid therapy (45.2%; p = 0.023) or was receiving MST at 2.5 mg/day (43.4%, p = 0.001). The RRs in the group receiving MST at ≥5 mg/day versus the patient group receiving MST at <5 mg/day were 10.6 vs. 10.3% within 1 year, 23.5 vs. 32.9% within 3 years and 32.2 vs. 41.3% within 5 years, respectively (log-rank, p = 0.028). The best cutoff value of the total steroid dose for serious steroid toxicity was 6405 mg, with a moderate accuracy of 0.717 determined using the area under the curve. Presence of diffuse pancreatic swelling [odds ratio OR) 1.745; p = 0.008) and MST at >5 mg/day were identified as predictors of relapse (OR 0.483; p = 0.001).

Conclusions

The RR could continue to increase for 7 years even under MST. Based on our analysis of the side effects of steroid therapy, MST at 5 mg/day for 2 (total 4625 mg) to 3 (total 6425 mg) years might be a rational and safe therapeutic strategy in terms of keeping the RR to <30% while avoiding potential steroid toxicity.
Literature
1.
go back to reference Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.CrossRefPubMed Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.CrossRefPubMed
2.
go back to reference Sarls H, Sarls JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—autonomous pancreatic disease. Am J Dig Dis. 1961;6:688–98.CrossRef Sarls H, Sarls JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—autonomous pancreatic disease. Am J Dig Dis. 1961;6:688–98.CrossRef
3.
go back to reference Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.CrossRefPubMed Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.CrossRefPubMed
4.
go back to reference Kamisawa T, Shimosegawa T, Okazaki W, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.CrossRefPubMed Kamisawa T, Shimosegawa T, Okazaki W, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.CrossRefPubMed
5.
go back to reference Gazale A, Chari ST, Zhang L, et al. Immunoglobin G4-associatedcholangitis:clinical profile and responce therapy. Gastroenterology. 2008;134:706–15.CrossRef Gazale A, Chari ST, Zhang L, et al. Immunoglobin G4-associatedcholangitis:clinical profile and responce therapy. Gastroenterology. 2008;134:706–15.CrossRef
6.
7.
go back to reference Hart PA, Kamisawa T, Witzig TE, et al. Long term outcomes of autoimmune pancreatitis:multicenter, international analysis. Gut. 2013;62:1771–6.CrossRefPubMed Hart PA, Kamisawa T, Witzig TE, et al. Long term outcomes of autoimmune pancreatitis:multicenter, international analysis. Gut. 2013;62:1771–6.CrossRefPubMed
8.
go back to reference Neomal SS, Nicholas I, Michael HC, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7:1089–96.CrossRef Neomal SS, Nicholas I, Michael HC, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7:1089–96.CrossRef
9.
go back to reference Shimosegawa T, Chari ST, Frulloni L, et al. International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.CrossRefPubMed Shimosegawa T, Chari ST, Frulloni L, et al. International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.CrossRefPubMed
10.
go back to reference Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheum. 2010;37:1380–5.CrossRefPubMed Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheum. 2010;37:1380–5.CrossRefPubMed
11.
go back to reference Culver EL, Sadler R, Simpson D, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 2016;111:733–43.CrossRefPubMed Culver EL, Sadler R, Simpson D, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 2016;111:733–43.CrossRefPubMed
12.
go back to reference Kamisawa T, Okazaki K, Kawa S, et al. Research committee for intractable pancreatic disease and Japan pancreas society. Japanese consensus guidelines for management of autoimmune pancreatitis. J Gastroenterol. 2010;45:471–7.CrossRefPubMed Kamisawa T, Okazaki K, Kawa S, et al. Research committee for intractable pancreatic disease and Japan pancreas society. Japanese consensus guidelines for management of autoimmune pancreatitis. J Gastroenterol. 2010;45:471–7.CrossRefPubMed
13.
go back to reference Nishimori I, Otsuki M. Study about steroid therapy for autoimmune pancreatitis. Annual reports of Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan (in Japanese). 2008;137–44. Nishimori I, Otsuki M. Study about steroid therapy for autoimmune pancreatitis. Annual reports of Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan (in Japanese). 2008;137–44.
14.
go back to reference Shimizu S, Naito I, Nakazawa T, et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol. 2015;50:1411–8.CrossRefPubMed Shimizu S, Naito I, Nakazawa T, et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol. 2015;50:1411–8.CrossRefPubMed
15.
go back to reference Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:961–70.CrossRefPubMed Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:961–70.CrossRefPubMed
16.
go back to reference Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011;46:834–42.CrossRefPubMed Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011;46:834–42.CrossRefPubMed
18.
go back to reference Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.CrossRefPubMed Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.CrossRefPubMed
19.
go back to reference Staa TP, Leufkens HGM, Abenhaim L, et al. Oral glucocorticoid and fracture risk:relationship to daily and cumulative doses. Rheumatology. 2000;39:1383–9.CrossRefPubMed Staa TP, Leufkens HGM, Abenhaim L, et al. Oral glucocorticoid and fracture risk:relationship to daily and cumulative doses. Rheumatology. 2000;39:1383–9.CrossRefPubMed
20.
go back to reference Hirano K, Tada M, Isayama H, et al. Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis. J Clin Gastroenterol. 2016;50:331–7.CrossRefPubMed Hirano K, Tada M, Isayama H, et al. Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis. J Clin Gastroenterol. 2016;50:331–7.CrossRefPubMed
21.
go back to reference Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6:364–6.CrossRefPubMed Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6:364–6.CrossRefPubMed
22.
go back to reference Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–29.CrossRefPubMed Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–29.CrossRefPubMed
23.
go back to reference Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.CrossRefPubMed Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.CrossRefPubMed
Metadata
Title
Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients
Authors
Kensuke Kubota
Terumi Kamisawa
Kazuichi Okazaki
Shigeyuki Kawa
Kenji Hirano
Yoshiki Hirooka
Kazushige Uchida
Hideyuki Shiomi
Hirotaka Ohara
Kyoko Shimizu
Norikazu Arakura
Atsushi Kanno
Junichi Sakagami
Takao Itoi
Tetsuhide Ito
Toshiharu Ueki
Takayoshi Nishino
Kazuo Inui
Nobumasa Mizuno
Hitoshi Yoshida
Masanori Sugiyama
Eisuke Iwasaki
Atshishi Irisawa
Toru Shimosegawa
Yoshifumi Takeyama
Tsutomu Chiba
Publication date
01-08-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1302-1

Other articles of this Issue 8/2017

Journal of Gastroenterology 8/2017 Go to the issue